Black Rock Inc. C4 Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,551,510 shares of CCCC stock, worth $19.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,551,510
Previous 905,006
402.93%
Holding current value
$19.6 Million
Previous $7.39 Million
184.42%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CCCC
# of Institutions
130Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$29.6 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$28.4 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$24.4 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$21 Million0.39% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.38MShares$18.8 Million0.59% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $210M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...